Clinical Trials

Demonstration of a Novel Approach Using Surface-Image Guidance to Improve Delivery of Breast Radiotherapy CTMS#: 18-0135

Cancer Type

Breast

ClinicalTrials.gov Identifier

NCT03799523

Principal Investigator

Eva Galvan M.D.

For more information about this study
View Details

About This Study

The first goal of this project is to validate the superiority of semi-permanent marks used in conjunction with specialized light-based surface imaging (SIGRT) in an effort to phase out the use of permanent tattoos for the investigator's patients. The secondary goal of this project is to validate the superiority of specialized light-based surface imaging for daily radiation set-up compared to standard-of-care imaging methods using ionizing radiation, such as weekly port films or cone-beam CT (CBCT) scans during a radiation therapy course for breast cancer.

What is the criteria to participate?

Note: This is only a partial list of eligibility criteria.

Inclusion Criteria:
Inclusion criteria
  • Age ≥ 18 years
  • Biologically female
  • Ability to provide informed written consent in either English or Spanish
  • Surgical pathology and staging scans must demonstrate Ductal carcinoma in situ (DCIS) or invasive breast cancer, Stages 0, 1, 2, and 3
  • Patient will undergo adjuvant radiation therapy as a part of multimodality breast cancer treatment with plans for tangent field radiation treatment with or without loco-regional lymph node targeting, based on the clinical judgement of the treating physician
  • Willingness to maintain temporary skin markings for a part of their of radiation therapy duration
  • Absence of any conditions that may affect ability to have either tattoos or skin markings, as discussed
Exclusion Criteria:
Exclusion Criteria

Exclusion Criteria:

  • Age < 18 years
  • Biologically non-female
  • Inability or unwillingness of subject to give written informed consent
  • Patients found at presentation to have very locally-advanced cancer (e.g. inflammatory breast cancer) or metastatic breast cancer (Stage 4)
  • Patients that will be treated with a deep-inspiration breath hold technique (typically younger patients being treated for left-sided tumors)
  • Current pregnancy, as this is a contraindication to receiving radiation therapy
  • History of prior radiotherapy to the chest wall or torso
  • Known allergy / sensitivity to standard medical marking tattoo ink (by design non-toxic, low-allergy), skin marking paint, or medical tape (e.g. Tegaderm)
  • Active drug or alcohol use or dependence evidenced by patient record and/or self-report that, in the opinion of the investigator, would interfere with adherence to daily radiation therapy